Economic value and clinical role of minimally invasive, biopsy-based diagnostics in non-small cell lung cancer

IF 2.9 3区 医学 Q3 ONCOLOGY
Jiayuan Guo MSc, Bo Franzén PhD, Rolf Lewensohn MD, PhD, Martin Hysek MD, PhD, Linus Jönsson MD, MSc, PhD
{"title":"Economic value and clinical role of minimally invasive, biopsy-based diagnostics in non-small cell lung cancer","authors":"Jiayuan Guo MSc,&nbsp;Bo Franzén PhD,&nbsp;Rolf Lewensohn MD, PhD,&nbsp;Martin Hysek MD, PhD,&nbsp;Linus Jönsson MD, MSc, PhD","doi":"10.1002/cncy.70152","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Precision oncology requires diagnostic sampling that delivers molecularly actionable material quickly and safely. In non-small cell lung cancer (NSCLC), core-needle biopsy (CNB) remains common. Yet fine-needle aspiration (FNA) has re-emerged with rapid on-site evaluation (ROSE), optimized cell blocks, and next-generation sequencing. The objective of this study was to compare the economic costs of FNA versus CNB with respect to an <i>FNA-first with predefined CNB escalation</i> strategy for NSCLC clinical pathways.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>The authors synthesized evidence on diagnostic adequacy, complication rates, and molecular performance of cytology versus core tissue. A microcosting framework decomposed total diagnostic episode costs into sampling, processing, complications, and remedial procedures. This framework was applied to Sweden’s Standardized Cancer Care Pathway for NSCLC using decision-tree modeling and sensitivity analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Modern cytology workflows with ROSE achieve a nondiagnostic sampling rate ≤6% and support programmed death-ligand 1 and broad next-generation sequencing with high mutation concordance to surgical specimens. Compared with CNB, FNA incurs fewer major complications and facilitates repeat sampling. In the Swedish illustration, an FNA-first pathway with ROSE reduced expected per-patient diagnostic cost by approximately 33% (7748 vs. 11,637 Swedish krona). The results were robust to ±50% variation in complication rates and ±5%–10% variation in adequacy.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Reframing <i>adequacy</i> around molecular fitness and time to actionability supports FNA where ROSE exists, with codified, same-episode CNB escalation. This approach advances safety, capacity, and timeliness without compromising molecular yield. The authors provide a transferable cost-consequence model and implementation checklist for health systems. Local recalibration is required for absolute cost values, and multisite calibration is encouraged to establish generalizability across the different settings.</p>\n </section>\n </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"134 10","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.70152","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncy.70152","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Precision oncology requires diagnostic sampling that delivers molecularly actionable material quickly and safely. In non-small cell lung cancer (NSCLC), core-needle biopsy (CNB) remains common. Yet fine-needle aspiration (FNA) has re-emerged with rapid on-site evaluation (ROSE), optimized cell blocks, and next-generation sequencing. The objective of this study was to compare the economic costs of FNA versus CNB with respect to an FNA-first with predefined CNB escalation strategy for NSCLC clinical pathways.

Method

The authors synthesized evidence on diagnostic adequacy, complication rates, and molecular performance of cytology versus core tissue. A microcosting framework decomposed total diagnostic episode costs into sampling, processing, complications, and remedial procedures. This framework was applied to Sweden’s Standardized Cancer Care Pathway for NSCLC using decision-tree modeling and sensitivity analyses.

Results

Modern cytology workflows with ROSE achieve a nondiagnostic sampling rate ≤6% and support programmed death-ligand 1 and broad next-generation sequencing with high mutation concordance to surgical specimens. Compared with CNB, FNA incurs fewer major complications and facilitates repeat sampling. In the Swedish illustration, an FNA-first pathway with ROSE reduced expected per-patient diagnostic cost by approximately 33% (7748 vs. 11,637 Swedish krona). The results were robust to ±50% variation in complication rates and ±5%–10% variation in adequacy.

Conclusions

Reframing adequacy around molecular fitness and time to actionability supports FNA where ROSE exists, with codified, same-episode CNB escalation. This approach advances safety, capacity, and timeliness without compromising molecular yield. The authors provide a transferable cost-consequence model and implementation checklist for health systems. Local recalibration is required for absolute cost values, and multisite calibration is encouraged to establish generalizability across the different settings.

非小细胞肺癌微创活检诊断的经济价值和临床作用
精确肿瘤学需要快速、安全地提供分子可操作材料的诊断取样。在非小细胞肺癌(NSCLC)中,核心针活检(CNB)仍然很常见。然而,随着快速现场评估(ROSE)、优化的细胞块和下一代测序,细针抽吸(FNA)重新出现。本研究的目的是比较FNA与CNB的经济成本,FNA优先与NSCLC临床途径的预定义CNB升级策略。方法对细胞学与核心组织的诊断充分性、并发症发生率和分子表现进行综合分析。微观成本框架将诊断事件的总成本分解为采样、处理、并发症和补救程序。通过决策树建模和敏感性分析,将该框架应用于瑞典的非小细胞肺癌标准化癌症治疗途径。结果使用ROSE的现代细胞学工作流程实现了非诊断采样率≤6%,并支持程序性死亡配体1和与手术标本具有高突变一致性的广泛下一代测序。与CNB相比,FNA发生的主要并发症较少,便于重复采样。在瑞典的例子中,带有ROSE的FNA-first途径将每位患者的预期诊断成本降低了约33%(7748瑞典克朗对11,637瑞典克朗)。结果对并发症发生率±50%的变化和充分性±5%-10%的变化具有稳健性。结论:围绕分子适应度和可操作时间重新构建充分性支持存在ROSE的FNA,并具有编码的,相同事件的CNB升级。这种方法在不影响分子产量的情况下提高了安全性、容量和及时性。作者为卫生系统提供了可转移的成本-后果模型和实施清单。绝对成本值需要局部重新校准,并且鼓励多站点校准以建立跨不同设置的通用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Cytopathology
Cancer Cytopathology 医学-病理学
CiteScore
7.00
自引率
17.60%
发文量
130
审稿时长
1 months
期刊介绍: Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书